<DOC>
	<DOCNO>NCT03069508</DOCNO>
	<brief_summary>This study phase IIa open label pilot study six month treatment clemizole hydrochloride ( 200 mg vs. 300 mg vs. 400 vs. 500 mg mg ) give orally TID subject hepatocellular carcinoma either await transplantation unresectable lesion .</brief_summary>
	<brief_title>Clemizole HCl Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description>The primary objective study : - Evaluate safety tolerability six month treatment clemizole hydrochloride ( 200 mg vs. 300 mg vs. 400 mg vs. 500 mg TID mouth ) subject diagnose hepatocellular carcinoma either await transplantation unresectable lesion . - Evaluate overall tumor response accord radiologic assessment stable disease , complete response ( CR ) , partial response ( PR ) , minor response ( MR ) , define Response Evaluation Criteria Solid Tumors ( RECIST ) , associate clemizole hydrochloride ( 200 mg vs. 300 mg vs. 400 mg vs. 500 mg , TID mouth ) - Evaluate pharmacokinetic ( PK ) activity clemizole hydrochloride ( 200 mg vs. 300 mg vs. 400 mg vs. 500 mg , TID mouth ) The secondary objective study : • Evaluate duration response , time progression , duration stable disease ( SD ) , overall survival associate clemizole hydrochloride ( 200 mg vs. 300 mg vs. 400 mg vs. 500 mg , TID mouth )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Males female , least 18 year age . 2 . Subjects diagnosis ( histologically proven ) hepatocellular carcinoma ( measurable CT MR contrast ) either await transplantation unresectable lesion receive prior experimental systemic treatment HCC additional therapy plan . 3 . Eastern Cooperative Oncology Group performance status 2 less . 4 . ChildPugh ( CP ) score A B . 5 . Life expectancy least 12 week . 6 . Elevated alphafetoprotein ( AFP ) level . 7 . Adequate hematologic ( platelet count , ≥60 ; hemoglobin , ≥8.5 g per deciliter ; prothrombin time international normalized ratio , ≤2.3 ; prothrombin time , ≤6 second control ) , hepatic ( albumin , ≥2.8 g per deciliter ; total bilirubin , ≤3 mg per deciliter [ 51.3 μmol per liter ] ; alanine aminotransferase aspartate aminotransferase , ≤5 time upper limit normal range ) , renal ( serum creatinine , ≤1.5 time upper limit normal range ) function . 8 . Electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality QT/QTc interval &lt; 450 millisecond male &lt; 470 millisecond female use Bazett 's correction ( QTc =QT/RR0.5 ; ICH Guidance E14 Clinical Evaluation QT/QTc Interval Prolongation Proarrhythmic Potential NonAntiarrhythmic Drugs ) 9 . Females childbearing potential ( intact uterus within one year since last menstrual period ) nonlactating negative serum pregnancy test . In addition , subject ( male female ) sexually active partner agree use one follow acceptable birth control method throughout study : 1. surgical sterilization ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) six month minimum 2 . IUD place least three month 3. barrier method ( condom diaphragm ) spermicide 4. surgical sterilization partner ( vasectomy six month ) 5. hormonal contraceptive least three month prior first dose study drug 10 . Willing able comply study procedure provide write informed consent 1 . Participation clinical trial use investigational agent within 30 day Study Visit 1 2 . Patients coinfected HIV 3 . Patients screen test positive antiHIV Ab 4 . Patients tumor mixed histology fibrolamellar variant , 5 . Pregnant lactate woman , 6 . Patients require systemic anticancer therapy , biologicresponse modifier 7 . Medical/psychological/social problem might affect study participation evaluation 8 . Eating disorder alcohol abuse within past two year , excessive alcohol intake ( &gt; 20 g per day female ( 1.5 standard alcohol drink ) &gt; 30 g per day male ( 2.0 standard alcohol drink ) ( standard drink contain 14 g alcohol : 12 oz beer , 5 oz wine 1.5 oz spirit ) ( 1.0 fluid oz ( US ) = 29.57 mL ) opinion investigator , alcohol use pattern interfere study conduct 9 . Drug abuse within last six month 10 . Patients absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 ; 11 . Abnormal TSH , T4 T3 12 . History clinical evidence follow : 1. variceal bleeding , difficult treat ascites , hepatic encephalopathy , CTP score &gt; 8 , 2. immunologically mediate disease ( e.g , rheumatoid arthritis , inflammatory bowel disease , severe psoriasis , systemic lupus erythematosus ) require intermittent nonsteroidal antiinflammatory medication management require frequent prolong use corticosteroid ( inhaled asthma medication allow ) 3. significant unstable cardiac disease ( e.g. , angina , congestive heart failure , uncontrolled hypertension , history arrhythmia ) 4. chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) associate functional impairment 5. severe uncontrolled psychiatric disease , include severe depression , history suicidal ideation , suicidal attempt psychosis require medication and/or hospitalization 13 . Patients body mass index &gt; 30 kg/m2 14 . Chronic use concomitant drug know prolong QT interval ( See Appendix E ) 15 . Concomitant use immunosuppressive immune modulate agent 16 . Patients serious condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete increase risk subject participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>